April 23rd 2021
The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.
Smoldering Multiple Myeloma Research Promising but Not Yet Translatable to Change in Care
June 2nd 2020As investigators have learned more about how to diagnose and categorize smoldering multiple myeloma (SMM), a new review article argues there’s insufficient data to evolve beyond a close observation approach.
Read More
AML, Multiple Myeloma Can Be Treated Simultaneously, According to Case Study
May 16th 2020It’s rare for a patient to be diagnosed with both acute myeloid leukemia and multiple myeloma at the same time, but a new case study suggests there are options to treat both diseases at the same time in such cases.
Read More
Chronic Transfusion Therapy for Sickle Cell Burdens Patients, Families, Study Says
May 15th 2020A new study based on interviews with families and patients undergoing chronic transfusion therapy for sickle cell disease finds that the therapy affects the families in ways that extend beyond health.
Read More
Extramedullary Disease in MM Tough to Treat, Even With Newer Therapies, Study Says
April 30th 2020Outcomes were worse for patients with multiple myeloma (MM) and extramedullary disease, and the authors said their findings indicate that evaluation of extramedullary response using imaging is needed in this group.
Read More
COVID-19 Increases Overall Risk of Death, Complications in Patients With Cancer, Study Shows
April 29th 2020Recent study results show that patients with cancer who develop coronavirus disease 2019 (COVID-19) are far more likely to die than those who develop COVID-10 but do not have cancer. Patients being treated with immunotherapy appear to be at particularly high risk.
Read More
Report Describes Patient With MM, COVID-19 Treated Successfully With Tocilizumab
April 25th 2020A new article outlining the experience of a patient with a history of multiple myeloma (MM) who contracted coronavirus disease 2019 (COVID-19) shows the interleukin-6 receptor inhibitor tocilizumab was an effective therapy.
Read More
What Is the Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting?
April 25th 2020Chimeric antigen receptor (CAR) T-cell therapy has been shown to improve health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma (LBCL). Currently, CAR T-cell therapies are primarily administered in inpatient settings. In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs.
Read More
A new poll conducted by the Kaiser Family Foundation shows a majority of Americans fear the worst of the coronavirus disease 2019 (COVID-19) pandemic is yet to come; reports of blood clots in patients with COVID-19 raise concerns; Veterans' Affairs medical facilities are struggling to cope with the pandemic.
Read More
Dr Elisabet Manasanch: Identifying Patients With Smoldering Multiple Myeloma Remains an Unmet Need
April 16th 2020Identifying patients with smoldering multiple myeloma is difficult as they often do not have any symptoms, but we could still do a much better job than what we are currently implementing, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Watch
FDA's Revised Blood Donation Guidance for Gay Men Still Courts Controversy
April 4th 2020The FDA has announced a relaxing of its restrictions on gay men being allowed to donate blood, in light of the coronavirus disease 2019 pandemic. Instead of 1 year, if a male has had sex with another male, he need only wait 3 months to donate blood.
Read More
Study Examines Fixed-Duration Therapy in Patients With MM Ineligible for Transplants
March 22nd 2020Newly diagnosed patients with multiple myeloma (MM) who are transplant-ineligible sometimes plan fixed-duration therapy to improve their quality of life. A new study examines the impact of that approach.
Read More
COVID-19 and Cancer: Practices Seek to Protect Patients, Providers From Growing Pandemic
March 21st 2020Some patients with cancer are more vulnerable than others, said Jeffrey Patton, MD, acting chief executive officer and president of physician services of OneOncology, as well as chief executive office of Tennessee Oncology, which is down to its last 14-day supply of personal protective equipment.
Read More
Hydroxycarbamide Therapy Shown to Improve Memory, IQ of Adolescents With Sickle Cell Disease
March 17th 2020In adolescent patients with sickle cell disease, hydroxycarbamide therapy was associated with improvements in neurocognition variables such as working memory, verbal memory, and nonverbal IQ, according to study findings.
Read More
Dr Elisabet Manasanch Discusses Current Standards of Treatment for Smoldering Multiple Myeloma
March 16th 2020There are studies exhibiting progression within treatment for smoldering multiple myeloma, but nothing has been FDA approved yet, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Watch
Dr C. Patrick Carroll Discusses Treating Patients With SCD-Related Pain Who Arrive in the ED
March 12th 2020When patients present to the emergency department (ED) with sickle cell disease (SCD)–related pain, they often have been experiencing that pain for days, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Watch
A year after being only the second person to be cured of HIV, the “London Patient” revealed his identity; BMS announced today that its combination therapy for multiple myeloma—elotuzumab, lenalidomide, and dexamethasone—failed its primary endpoint of progression-free survival in its phase 3 ELOQUENT-1 trial; Biocon and Mylan N.V. announced that the FDA accepted their biologics license application (BLA) for MYL-14020, a proposed biosimilar to bevacizumab (Avastin), for review.
Read More
FDA Approves Isatuximab-irfc for Treatment of Relapsed Refractory Multiple Myeloma
March 5th 2020Isatuximab-irfc, sold as Sarclisa, in combination with pomalidomide and dexamethasone, was approved this week by the FDA for the treatment of adults with relapsed refractory multiple myeloma who have received at least 2 prior therapies.
Read More
Dr Adam Olszewski on Research Still Needed on Palliative Care Services in Blood Cancers
March 3rd 2020More data is needed to get wider acceptance of the use of palliative care services for patients with blood cancers, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.
Watch
Higher Microbiota Diversity in Hematologic Cancer Treatment Could Lower Mortality Risk, Study Finds
February 27th 2020For patients undergoing allogeneic hematopoietic cell transplantation, higher diversity of intestinal microbiota at the time of neutrophil engraftment was linked with lower mortality, according to study findings published today.
Read More